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ABSTRACT 
 
Background: The introduction of antipsychotics has been a significant milestone in the 
treatment of schizophrenia. However, these agents have several important side effects, such as 
metabolic syndrome. Options to curb these side effects include a change in the treatment 
option, changes in patients’ lifestyle, and the addition of other medications such as metformin, 
among others. Thus, this study investigated whether dose reduction of an injectable 
antipsychotic, flupenthixol decanoate, would result in improvement of metabolic syndrome 
parameters in a cohort of first-episode schizophrenia patients in South Africa. 
Methods: The study included 33 participants recruited at the Tygerberg and Stikland Hospitals 
in the Western Cape Province, South Africa. The metabolic syndrome profiles of all 33 
participants were compared at baseline and at point of relapse. All participants were given a 
monthly dose of an injectable antipsychotic, flupenthixol decanoate, which was gradually 
reduced until the participant relapsed or was off treatment. Adherence to treatment was 
guaranteed as all participants had to visit the healthcare facility to receive their injectable. 
Results: The majority of the participants were colored (75.8%). Most (64%) of the participants 
were overweight. The mean time to relapse was 39.2 weeks, and by week 32, almost half of 
the participants had relapsed. A significant change was observed for weight (p = 0.018), waist 
circumference (p = 0.006) and fasting glucose (p = 0.045). There were no significant changes 
in the lipid parameters following the antipsychotic dose reduction. 
Conclusion: Antipsychotic dose reduction resulted in weight loss; however, the majority of 
patients relapsed with some having important consequences. Further studies are needed to 
understand the dynamics of treatment discontinuation in schizophrenia patients; however, 
clinicians should closely monitor patients taking antipsychotics as metabolic syndrome 
negatively impacts on the patients’ quality of life. 
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PREFACE 
The current research was part of a broader study which was a randomized, double-blinded, 
placebo-controlled investigation that involved subjects who had been successfully treated for 
2 to 3 years after a first episode of schizophrenia, schizoaffective or schizophreniform disorder 
and who voluntarily opted to discontinue antipsychotic treatment under supervision (Emsley 
et al., 2014).The data for this study were collected from patients recruited at Tygerberg and 
Stikland Hospitals catchment area in the Western Cape, South Africa. This is a secondary 
quantitative study which looked into whether treatment discontinuation had any effect on the 
individual metabolic syndrome parameters. The secondary analysis of the data was done under 
the supervision of Professor Bonginkosi Chiliza who was an investigator in the original study. 
This study uses data collected by other researchers; however, has never been submitted under 
the current topic and investigating the parameters earlier mentioned to any tertiary institution. 
Where the use of other people’s work has been done, this has been acknowledged in the text. 
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LIST OF ABBREVIATIONS 
 
SGA   : Second-generation antipsychotic 
FGA   : First-generation antipsychotic 
HDL   : High-density lipoprotein 
LDL   : Low-density lipoprotein 
VLDL   : Very low-density lipoproteins 
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AN   : Arcuate nucleus 
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SD   : Standard deviation 
SE   : Standard error 
DSM-IV  : Diagnostic and statistical manual of mental disorders, fourth edition 
Tdp   : torsades de pointes 
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LIST OF PARAMETERS AND UNITS USED TO MEASURE 
 
Parameter measured Unit of measurement  
BMI (body mass index) : Kg/m2  
Diastolic blood pressure : mmHg 
Fasting blood glucose : mmol/L 
HDL (high densisity lipoprotein) : mmol/L 
LDL (low density lipoprotein) : Mm/L 
Systolic blood pressure : mmHg 
Triglycerides : mmol/L 
Waist circumference : Cm 
Weight : Kg 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Background 
Antipsychotics have been a great milestone in the treatment of schizophrenia. From the 
discovery of the first antipsychotic chlorpromazine to the further discovery of more and 
differentiating into different classes, namely “first-generation antipsychotics” to “second-
generation antipsychotics.” However, these agents present with several serious untoward 
effects. The life expectancy of people suffering from mental illness is reduced by at least 7-24 
years according to a systematic review published in 2014 (Chesney, Goodwin and Fazel, 2014). 
The study also noted that suicide among this population is ten times higher than the general 
population. Unfortunately, this figure is further fueled by the association of mental illness and 
substance abuse (Whiteford et al., 2013). 
Antipsychotics are widely used for the treatment of schizophrenia and other psychiatric 
disorders (Chang and Lu, 2012); however, they contribute to the public health problem of 
metabolic syndrome as well as its increasing prevalence (Chadda et al., 2013). The increase in 
prevalence may also be attributed to modern civilization (Wang et al., 2010). Metabolic 
syndrome involves a cluster of abnormalities including elevated fasting blood glucose, low 
HDL, increased LDL, obesity and elevated blood pressure (Grundy et al., 2004). These 
adversities lead to cerebrovascular disease,  diabetes mellitus and cardiovascular complications 
(Kannel and Daniel, 2012) further leading to the high rates of mortality in people with 
schizophrenia (Schoepf et al., 2012).  
There is inadequate literature available on antipsychotic dose reduction. However, a study in 
China (Wu et al., 2014) not only examined the effects of antipsychotics on glucose and lipid 
metabolic parameters on a cohort of 131 Chinese patients with schizophrenia but also looked 
at the effects of antipsychotic discontinuation on these parameters. The study comprised of 
drug naïve participants, those treated with antipsychotics as well as participants who were 
treated and later discontinued treatment. Unfortunately, the study only confirmed what is 
already known of the metabolic adversities caused by antipsychotics. No improvement was 
noted in the glucose and lipid profiles of participants who had discontinued antipsychotic 
treatment. Most of the available literature looks at individual metabolic syndrome (MetS) risk 
factors instead of looking at individuals with full-blown MetS (people who meet at least three 
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of the five criteria),  and not many of those studies have investigated dose tapering as a way to 
undo MetS. 
The above-mentioned study is similar to our study, in which we examined the glucose and lipid 
profiles of participants with schizophrenia who had undergone remission. The participants 
were weaned off treatment in monthly intervals (reduction factor 0,75 for all participants). 
Glucose and lipid profiles were recorded at baseline and 6 monthly intervals. This study was 
conducted in an attempt to find out if gradual antipsychotic medication withdrawal could 
reverse metabolic adversities. 
 
1.2 Research question 
Does dose reduction of an injectable antipsychotic result in weight loss? 
 
1.3  Problem statement 
Various studies in the literature have investigated the effects of antipsychotics on weight and 
BMI and the management thereof. Of interest in the current study were the effects of dose 
reduction on the major phenotypical aspects of metabolic syndrome such as weight gain and 
lipid profile. The findings of this study may assist in determining which parameters to monitor 
when discontinuing antipsychotic therapy. 
 
1.4 Aim  
The aim of this study was to investigate the effects of antipsychotic treatment dose reduction 
on the participants' metabolic parameters. 
 
1.5 Specific objectives 
To compare participants' metabolic syndrome criteria at baseline and point of relapse. 
To determine whether there is a relationship between metabolic syndrome and socio-
demographic factors. 
To determine the prevalence of metabolic syndrome across different socio-demographic 
factors. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Introduction 
According to the DSM-V, schizophrenia is diagnosed when an individual experiences two or 
more of the following symptoms for at least one month (or longer): delusions, hallucinations, 
disorganized speech, grossly disorganized or catatonic behavior and negative symptoms. 
Although no definite etiological basis for this condition has been found, it is thought that factors 
such as environment, genetics, neurodevelopment could be the cause (Weinberger, 2017). To 
support the latter statement, Koenig et al. (2002) discovered that this condition may be genetic 
or even develop as a result of the unborn baby being exposed to prenatal stress during the 
second or third trimester of pregnancy. However, there are quite a few infectious disease 
studies that have found a link between schizophrenia and elevated Toxoplasma gondi 
antibodies in patients with schizophrenia (Yolken et al., 2002; Ghorbanpoor et al., 2010). 
Before the development of antipsychotics, patients who had psychosis would have been 
institutionalized until their symptoms improved (Gronfein, 2012). This probably had a toll on 
the health system. Fortunately, the development of antipsychotics meant that patients could 
now be treated at home and only required hospitalization when their symptoms worsened 
(Kane, 1988a). With that being said, antipsychotics did come with a whole host of adverse 
effects and the most well-known being metabolic syndrome (Tschoner et al., 2007), which has 
been observed at therapeutic doses. Not all antipsychotics contribute equally to this adverse 
effect and research has shown that compared to older generation antipsychotics, the newer 
generation antipsychotics are more likely to cause metabolic syndrome (Kane, 1988a).  
Metabolic syndrome (MetS) further complicates the treatment of schizophrenia as it is likely 
to contribute to high rates of mortality (Saloojee, Burns and Motala, 2016). Mortality arises 
from the secondary complications of metabolic syndrome such as diabetes and cardiovascular 
adversities. Some patients may present with risk factors before treatment, and in most cases, 
lifestyle behaviors of people with schizophrenia such as inactivity and poor diet have an 
additive effect on MetS (Chadda et al., 2013). The increased risk of metabolic syndrome in 
young patients with first-episode psychosis could also be due to elevated clinical markers such 
as LDL, HDL, triglycerides and fasting blood glucose in addition to unhealthy lifestyle 
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behaviors (Smith, Griffiths and Horne, 2016). This could result in high rates of non-adherence 
to treatment amongst patients as well as relapse (Tschoner et al., 2007). Drugs have been 
developed recently (sertindole) to minimize adverse events, but this has not always proven 
successful, and newer agents are not necessarily more superior than their older counterparts 
(Cincotta and Rodefer, 2010). 
Apart from metabolic syndrome, some researchers believe antipsychotics could be associated 
with a reduction in brain volume as well as dopamine receptor sensitization which could lead 
to relapse and illness progression(Goff et al., 2017). Treatment of schizophrenia is based on 
the phase of illness (acute or maintenance phase)(Hui et al., 2019). Some researchers believe 
maintenance treatment is the gold standard in antipsychotic therapy (Emsley, Kilian and 
Phahladira, 2016). However, one should be aware that guidelines vary based on the country of 
origin, and there is no one size fits all approach in the treatment of schizophrenia(Hui et al., 
2019). The same systematic review (Hui et al., 2019) discovered that some guidelines suggest 
a two-year or 2-5 year period on maintenance therapy while others suggested maintenance 
treatment indefinitely. 
 
2.2 Metabolic Syndrome overview  
Metabolic syndrome, an umbrella term to describe hypertension, reduced high-density 
lipoprotein, hyperglycemia, hypertriglyceridemia as well as an increase in waist circumference 
(Kane, 1988a; Chadda et al., 2013), has been noted to be a significant contributor to the 
mortality of patients with schizophrenia (Grundy et al., 2004; Factors et al., 2011; 
Fleischhacker et al., 2013; Young, Taylor and Lawrie, 2015; Saloojee, Burns and Motala, 
2016). Although some researchers might argue that MetS is intrinsic to schizophrenia 
(Freyberg et al., 2017), given the sedentary lifestyle of most people with schizophrenia, others 
claim antipsychotic medicines do not cause metabolic syndrome but facilitate its progression 
(Factors et al., 2011). Wysokiński, Dzienniak, and Kłoszewska (2013) found that disturbances 
in lipid and glucose profile contributed to worsening cognitive function in patients with 
schizophrenia. Diabetes, hypertension and obesity have shown to have similar susceptibility 
genes (Cheung and Li, 2012). The tragedy is that the manifestation of multiple factors that 
cause MetS in a person, may aggravate depression in such patients and thus presenting a 
challenge for clinical improvement (Vallance, 2009). Several factors lead to metabolic 
syndrome (resulting in cardiac complications as well), e.g. smoking, obesity, hypertension and 
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dyslipidemia. However, there is no clear answer as to whether all these factors are additive to 
the cause of MetS or they work together, eventually causing metabolic syndrome (Holt and 
Mitchell, 2015). Different criteria have been identified to determine if an individual should be 
considered as suffering from metabolic syndrome (Table 1). 
 
Table 1: Criteria for metabolic syndrome according to the South African dyslipidemia 
guideline consensus statement: 2018. A person is said to have metabolic syndrome when they 
meet 3/5 criterion 
Criterion Specification 
Fasting glucose >5.6 mmol/L 
Hypertriglyceridemia >1.7 mmol/L 
Low density lipoprotein cholesterol <1 mmol/L men, <1.3 mmol/L women 
Systolic blood pressure >130 mmHg 
Diastolic blood pressure >85 mmHg 
Waist circumference >90 cm men, >80 cm women 
Table from the South African dyslipidemia guideline consensus statement: 2018 
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Figure 1: Factors contributing to metabolic syndrome. 
 
2.2.1 Prevalence of antipsychotic-induced Metabolic Syndrome 
Comparing prevalence studies by different researchers poses a challenge since there are 
varying definitions of MetS (Cameron, Shaw and Zimmet, 2004). The global prevalence of 
MetS was reported as 32.5% (Mitchell et al., 2013). In their study, at least 1 out of 3 patients 
with schizophrenia who were included in prevalence studies had MetS (Mitchell et al., 2013). 
These people were often from low- and middle-income countries where there might be very 
few physicians who can diagnose schizophrenia; some patients do not even present themselves 
to a healthcare facility at all. There are global studies looking into MetS in schizophrenia 
(Saloojee, Burns and Motala, 2016). However, one study was able to document prevalence in 
27 countries(Mitchell et al., 2013). A different study noted that MetS was more prevalent in 
the younger generation receiving second-generation antipsychotics(Chadda et al., 2013). 
Young people on antipsychotics present with an incidence rate of 0.20/1000/year (Messias, 
Chen and Eaton, 2007). About 50% of patients with schizophrenia are overweight (Mitchell et 
al., 2013). There seem to be contradictory findings when it comes to prevalence according to 
gender (Chiliza et al., 2015). Some studies found MetS more prevalent amongst females (De 
Hert, Schreurs and D, 2008; Chadda et al., 2013; Saklayen, 2018). Contrarily, Fleischhacker et 
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al. (2013) discovered that MetS was more prevalent amongst males. An increase in BMI was, 
however, associated with non-substance use (Chiliza et al., 2015). Age did not necessarily have 
a significant contribution to prevalence; it was the duration of treatment that had an influence 
(Mitchell et al., 2013).  
 About 15% of the world’s population resides in Africa, and the figures are estimated to 
increase to approximately 40% by the end of the current century (Frankema and Waijenburg, 
2018). However, only 0.001% of all schizophrenia patients recruited in global studies are from 
Africa (Purgato, Adams and Barbui, 2012). Therefore, information on antipsychotic-induced 
MetS in Black African people is limited (Saloojee, Burns and Motala, 2016). A recent cross-
sectional study done in South Africa documented a metabolic syndrome prevalence rate of 
23,2% in their cohort, with South African Indians being at a higher risk of MetS compared to 
people of Black African (Saloojee, Burns and Motala, 2016). Race seems to also play a role in 
studies that included people of different ethnic groups (Cameron, Shaw and Zimmet, 2004). 
Low- and middle-income countries may experience difficulty in estimating prevalence since 
many cases remain undocumented as patients never make it to healthcare facilities for treatment 
(Saloojee, Burns and Motala, 2016). Prevalence studies might also fail to deliver a clear global 
picture in the sense that they compare different populations subjected to varying inclusion 
criteria and study designs (Cameron, Shaw and Zimmet, 2004; Chadda et al., 2013).  
 
2.3 Antipsychotics 
Before the successful discovery of the first effective antipsychotic chlorpromazine, in the late 
1949’s, scientists had several failed attempts in treating psychosis using (Chang and Lu, 2012; 
Gronfein, 2012). However, these failed attempts led to the realization that there was a need for 
other phenothiazine derivatives with similar effects, and eventually, chlorpromazine was 
successfully synthesized (Dimitrelis and Shankar, 2016). Antipsychotics have not only 
improved the treatment of mental illnesses such as schizophrenia but have also decreased the 
need for hospitalization because patients can now receive their treatment at home (Gronfein, 
2012). This has improved compared to the past, where patients had to be hospitalized for long 
periods while receiving treatment (Abdelmawla and Mitchell, 2006). These drugs also happen 
to be one of the most prescribed drugs on the market today (Balt et al., 2011). In South Africa, 
17 drugs have been approved for the treatment of psychosis (Rossiter et al., 2016). A list of 
these side effects are shown in Figure 2. The top 6 frequently encountered side effects 
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associated with the antipsychotics registered for use in South Africa include extrapyramidal 
effects, orthostatic hypotension, weight gain, dizziness, headache and sedation (Figure 2). 
 
Figure 2 : Source: (Rossiter et al., 2016) 
 
2.3.1 Advancement to newer drugs 
 Schizophrenia is not only one of the most distressing mental illness for both patient and 
caregiver, but also quite costly to treat (Chisholm et al., 2008). The degree to which different 
antipsychotics contribute to the different metabolic adversities differs (Stroup et al., 2011). 
Hence clinicians could decide to switch from one antipsychotic to one better tolerated by the 
patient (de Silva et al., 2016). During recent years, there has been a shift from first-generation 
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antipsychotics (FGA) to the second-generation (Leucht, Kissling and Davis, 2009) 
antipsychotics (SGA). The main difference between FGA and SGA is that FGA highly 
antagonizes at the dopamine D2 receptors; newer drugs (SGA) have more affinity for other 
neuro-receptors such as serotonin (Tashkin et al., 2008). Another point to note is that SGA 
present with a better tolerability profile compared to FGA, as well as a reduction in cognitive 
impairment (Kane, 1988a). However, SGA have been linked to weight gain and metabolic 
syndrome (Kane, 1988a; Factors et al., 2011). This could potentially affect treatment adherence 
(Tschoner et al., 2007) since these medicines often come with a warning of possible 
hyperglycemia and diabetes (Factors et al., 2011). Therefore patients taking antipsychotics 
require regular monitoring by the treating clinicians. The use of antipsychotic drugs is not 
limited to schizophrenia alone. Despite all the side effects of SGA, they remain the treatment 
of choice for most psychiatrists (Leucht, Kissling and Davis, 2009). However, due to cost, 
many lower- and middle-income countries still use first-generation antipsychotics as they are 
more affordable (Chisholm et al., 2008). The cost of these agents (SGA) might have caused 
the spark in the debate about their superiority to first-generation antipsychotics (Leucht et al., 
2009). 
All clinicians would agree that the most important decision when treating schizophrenia lies in 
which antipsychotic will best work for the patient(Davis, Chen and Glick, 2003). First-
generation antipsychotics are believed to effectively treat positive symptoms in schizophrenia 
which include delusions and hallucinations while they are less effective in treating the negative 
symptoms and this is where second-generation antipsychotics are thought to be quite effective 
(Chang and Lu, 2012). In a systematic review comparing antipsychotic efficacy, Leucht et al. 
discovered that four (amisulpride, clozapine, olanzapine and risperidone) out of nine second-
generation antipsychotics were more effective in primary outcomes compared to first-
generation antipsychotics (Leucht et al., 2009). Extrapyramidal side effects remained the main 
concern with first-generation antipsychotics; however, when it came to metabolic side effects 
such as weight gain, there was no superiority (in terms of side effect profile) of second-
generation antipsychotics compared to the first-generation antipsychotics. The study also noted 
that SGAs cause just as much weight gain as FGAs except for aripiprazole and ziprasidone 
which were more weight neutral. One thing is sure, regardless of whether an antipsychotic is 
an SGA or FGA, the effect it has on the different metabolic syndrome parameters 
differs(Chadda et al., 2013). 
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The introduction of second-generation antipsychotics gave an impression of new, safer and 
more efficacious drugs into the market. In 1996 a Dutch-manufactured atypical antipsychotic 
drug, sertindole, was introduced into the market and had passed as a better-tolerated drug in 
clinical trials (Cincotta and Rodefer, 2010). Its reign was, however, short-lived when it was 
later withdrawn in 1998 because of discovering that it caused prolongation of the QT interval 
(Cincotta and Rodefer, 2010). This shows that even with newer drugs being introduced, it does 
not necessarily mean they are superior to older antipsychotics. Sertindole was later brought 
back into the market by certain European countries because of specific characteristics that were 
found more desirable and overshadowed its safety concerns (Cincotta and Rodefer, 2010). In a 
double-blinded study by Leucht et al. again sertindole was found not to be any more superior 
to the first generation antipsychotics in treating both positive and negative symptoms (Leucht 
et al., 2009). 
 
2.4 Complications presented by antipsychotics 
2.4.1 Weight gain 
Antipsychotic use is associated with weight gain(de Silva et al., 2016). It is commonly believed 
that the main contributors to weight gain or obesity are lack of exercise, or physical inactivity 
and consumption of too many calories (Manu et al., 2015). Weight gain can be determined by 
measuring weight, however measuring waist circumference is useful when measuring the 
increase in abdominal fat deposition and this approach is much more efficient in determining 
risks of developing secondary illnesses such as type two diabetes (Fleischhacker et al., 2013). 
People on antipsychotics are generally more prone to weight gain or obesity compared to the 
general population (Chang and Lu, 2012). Antipsychotics can cause metabolic syndrome in 
ways that cannot be explained by weight gain alone (Kang and Lee, 2015). This is supported 
by evidence in a study that discovered that unlike the prevalence of weight gain, the prevalence 
of metabolic syndrome differed for the three groups that were being studied, revealing that 
weight gain does not always correlate with disturbances in lipid and glucose homeostasis (Kang 
and Lee, 2015). One of the theories of antipsychotic-induced weight gain is that weight gain is 
mediated through peripheral messengers which act through pathways in the hypothalamic 
region known as the arcuate nucleus (AN) which causes secretions of a peptide hormone 
(ghrelin) from the stomach mucosa which results in the expression of neuropeptide Y (NPY) 
and agouti-related protein (AgRP) by the hypothalamus (Luquet et al., 2005; Balt et al., 2011). 
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These neurons are responsible for appetite and weight gain. Balt et al. (2011) were also able to 
cite gene alleles (HTR2C −759C and the LEP −2548G) that were most likely to predispose 
patients to weight gain. When different atypical antipsychotics were compared to one another, 
it was found that the extent to which each antipsychotic contributed to weight gain differed 
(Fleischhacker et al., 2013).  
Although antipsychotics may contribute to an increase in BMI (Chiliza et al., 2015), the 
increase was found to be related to improved cognition and memory performance (Luckhoff et 
al., 2019), which was however independent of the degree of antipsychotic exposure. An 
increase in BMI, although not physically appealing,  appears to improve cognitive function in 
patients with schizophrenia. Studies on clozapine have shown that it has more significant 
metabolic adversities compared to other antipsychotics; however, it has been found to be more  
superior in treatment-resistant schizophrenia (Nielsen, Skadhede and Correll, 2010a).  
Pharmacological strategies to counteract weight gain have been proposed, especially for cases 
where switching antipsychotics to those with less cardio-metabolic adversities is not feasible 
(De Hert et al., 2008). These strategies involve the use of antidiabetic drug metformin 
(Mahmood, Naeem and Rahimnajjad, 2013; Mizuno et al., 2014; de Silva et al., 2016). Other 
strategies include exercise, a balanced diet as well as switching antipsychotics from those that 
have a high tendency of causing weight gain to those which are more weight neutral. 
 
2.4.2 Diabetes 
2.4.2.1 Glucose homeostasis  
Like most systems in the body, glucose homeostasis is regulated through a negative feedback 
mechanism. This feedback mechanism involves the B cells which are found on the islets of 
Langerhans in the pancreas, which have four types of cells which produce four different 
hormones (Pandol, 2015), namely:  
• Beta cells - insulin 
• Alpha cells - glucagon 
• Omega cells - somatostatin 
• F cell - pancreatic polypeptide 
The B cells work with the insulin-sensitive cells in the body. When glucose levels rise in the 
body, the B cells of the pancreas are stimulated to secrete insulin which sensitizes cells to 
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glucose (Laurie Kelly, 2005). Muscles use glucose as the primary source of energy, and in 
order to absorb glucose, they require insulin to facilitate the transport of glucose into the cells. 
Thus, the increase in insulin results in glucose uptake by the cells maintaining homeostasis. In 
the case of insulin resistance, as seen in the majority of obese people, the B cells are stimulated 
to secrete increased amounts of insulin in response to the reduced sensitivity of the cells (to 
overcome insulin resistance) in order to maintain homeostasis. Eventually, because of insulin 
resistance, the B cells are unable to meet the increased demand for insulin, and this results in 
elevated plasma glucose levels (hyperinsulinemia). The elevation in plasma glucose initially 
causes impaired glucose tolerance and further damage to the B cells causing further increases 
in plasma glucose, and eventually, full-blown type two diabetes develops (Kahn, Cooper and 
Del Prato, 2014). The long-term consequences of hyperglycemia are thickening of capillary 
membranes as well as narrowing of blood vessels that supply vital organs with blood, and this 
can lead to atherosclerosis, retinopathy, neuropathy and ulceration or gangrene. Severe 
peripheral neuropathy puts the patient at risk of lower extremity amputations (Pemayun et al., 
2015). 
2.4.2.2 Diabetes mellitus in patients taking antipsychotics 
Although there are genetic factors involved in some cases of diabetes mellitus globally, we 
have witnessed an increase in cases of obesity and as a result, this has contributed to the 
increased prevalence of type 2 diabetes (Kahn, Cooper and Del Prato, 2014), not to forget 
environmental factors involved. Environmental factors can include but are not limited to a 
sedentary lifestyle and a high-calorie diet. Some researchers believe disturbances in glucose 
homeostasis in patients taking antipsychotics is a result of “antipsychotic-induced weight 
gain”; this is an indirect association which could be explained by the decrease in peripheral 
insulin sensitivity (Nielsen, Skadhede and Correll, 2010b). Another exciting discovery was that 
schizophrenia and type 2 diabetes mellitus share the same intrinsic inflammatory pathways 
(Perry et al., 2016), this was justified by first episode psychosis later developing into full-blown 
schizophrenia and likewise pre-diabetes later on leading to diabetes. Both these events occur 
concurrently in people diagnosed with both schizophrenia and type 2 diabetes mellitus.  
 
However, there are many cases of diabetes mellitus in people living with schizophrenia that 
remain undiagnosed making it difficult to determine prevalence rates as schizophrenia and 
diabetes share similar risk factors (Fernandez-Egea et al., 2009). Literature has remained quite 
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consistent though in reporting a two to three-fold higher diabetes mellitus rate in schizophrenia 
patients compared to the general population (Holt and Mitchell, 2015). As mentioned earlier, 
some researchers believe that MetS could be intrinsic to schizophrenia (Cohn et al., 2006; 
Venkatasubramanian et al., 2007). At least 10% of patients with schizophrenia develop 
diabetes in their lifetime, putting people with schizophrenia at 2.5 times greater risk of 
developing diabetes compared to the general population (Pillinger et al., 2017). Fernandez-
Egea et al. (2009) discovered that drug-naïve patients with psychosis displayed abnormal 
glucose tolerance before being exposed to any antipsychotic medication. It seems that insulin 
plays a crucial role in the development of MetS and diabetes mellitus in patients (Tomono et 
al., 2008). Venkatasubramanian et al. (2007) believe that the answer lies in the deficiency of 
insulin growth factor-1 (crucial for insulin sensitivity) which they found to exist in 
antipsychotic-naïve patients with schizophrenia. A deficiency in IGF-1 could potentially result 
in insulin resistance leading to diabetes. Fleischhacker et al. (2013) also concluded that 5.9% 
of their participants had pre-existing metabolic syndrome at baseline prior to any treatment, 
however, their explanation was attributed to unhealthy behaviors like smoking, alcohol, 
sedentary lifestyle which is in line with the other researchers findings in earlier studies (Factors 
et al., 2011).  
 
2.4.3 Dyslipidemia 
Hepatic lipase, which is found in the liver, is responsible for the hydrolysis of triglycerides 
(TG) and phospholipids into low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL) particles. This process results in smaller and denser LDL particles (carry cholesterol to 
tissues and results in artery plaque formation) and a higher reduction in HDL (removes 
cholesterol from circulation and returns it to the liver for excretion). The human body requires 
higher levels of HDL, the so-called “good cholesterol” and lower levels of LDL, which is 
known as “bad cholesterol”. The next stage is an increased synthesis of apolipoprotein B, which 
leads to an increase in triglyceride containing very low density lipoprotein (VLDL) particles 
(Ayyobi and Brunzell, 2003). 
Dyslipidemia is the major contributing factor to the complications of metabolic syndrome, 
which is mainly high levels of free fatty acids, TG, LDL and rather low levels of HDL 
(Kolovou, Anagnostopoulou and Cokkinos, 2005). Secondary causes of dyslipidemia include: 
• Liver disease 
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• Hypothyroidism 
• Kidney disease 
• Excessive alcohol consumption 
• Diabetes mellitus 
• Steroid drugs 
• Progestins 
• Antiretrovirals, e.g. stavudine 
• retinoids 
 
2.4.3.1 Pathophysiology of Dyslipidemia 
Cholesterol is notoriously known for causing cardiac conditions as well as blocking arteries; 
however, the body requires cholesterol to synthesize hormones, bile acid, plasma membranes 
and myelin sheath of neurons (Zhang and Liu, 2015). An imbalance in lipid profile has been 
known to cause coronary heart disease, atherosclerosis, cerebrovascular disease as well as 
peripheral vascular disease.  
Dyslipidemia is caused by both environmental (sedentary lifestyle, diet, smoking) and genetic 
factors.  
When LDL remains in plasma for too long, it becomes oxidized generating free radicals, and 
that oxidation renders it atherogenic which causes atherosclerosis and even worsens the 
inflammation of blood vessels. Most atherosclerosis-related deaths are as a result of coronary 
heart disease (Weisfeldt and Zieman, 2007). Weight gain, as well as insulin resistance, are the 
main driving forces predisposing individuals to dyslipidemia (Ayyobi and Brunzell, 2003; 
Kang and Lee, 2015). The adipose tissue of overweight individuals produces adipokines 
(cytokines), which also contribute to the development of metabolic syndrome (Tomono et al., 
2008). People with increased intra-abdominal fat have increased hepatic lipase activity, which 
results in hydrolysis of HDL and LDL (Ayyobi and Brunzell, 2003). People with obesity 
release reduced amounts of adiponectin from adipose tissue, which is believed to be the cause 
of insulin resistance and a fatty liver (Buechler, Wanninger and Neumeier, 2011). Adipokines 
cause atherogenesis directly by acting on the arterial walls or through other metabolic risk 
factors. HDL primarily disturbs the process of atherogenesis through reverse transportation of 
LDL and VLDL (Hao and Friedman, 2014). Plaque buildup can also cause thrombosis when 
the plaque on the vessel ruptures worsening coronary heart disease. Incorporating exercise, 
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maintaining a healthy weight and reducing alcohol consumption are just some of the ways 
individuals can improve lipid imbalance (Kolovou, Anagnostopoulou and Cokkinos, 2005). 
Dyslipidemia is pharmacologically treated using a class of drugs called statins. These drugs act 
by binding and inhibiting an enzyme HMG-CoA reductase; this increases the hepatic extraction 
of LDL from the blood, therefore, reducing free-flowing LDL (McFarland et al., 2014). 
 
2.4.4 Hypertension 
 2.4.4.1 Normal blood pressure 
Blood pressure is regulated by a system called the renin-angiotensin system which uses 
aldosterone to control the movement of sodium through the distal tubule of the nephron by 
increasing the number of sodium permeable channels as well as activating the sodium-
potassium ATPase pump. The pump removes sodium from the lumen into the extracellular 
cavity returning sodium particles into circulation. The movement of sodium is accompanied by 
water. The presence of sodium and water in the extracellular cavities results in a larger blood 
volume increasing the mean arterial pressure. When sodium is retained, potassium is excreted. 
An increase in extracellular potassium, on the other hand, results in the activation of 
angiotensin II (from precursor enzyme angiotensin from the liver) which results in the 
stimulation of the kidneys adrenal cortex to release aldosterone which in turn brings blood 
potassium levels back to normal (Harrison-Bernard, 2009). 
 
2.4.4.2 Hypertension in metabolic syndrome 
People with metabolic syndrome have been found to display defective baroreceptor responses 
(Brozmanova et al., 2009). The mechanism by which hypertension occurs in metabolic 
syndrome is not clear (Tomono et al., 2008). An increase in visceral fat, as well as insulin 
resistance, have been thought to be the major contributors to increased blood pressure 
(Ferrannini et al., 1997). Visceral fat can secrete adipocytokines, namely: 
• interleukin-6 
• necrosis factor alpha 
• non-esterified fatty acids 
• tumor necrosis factor alpha; 
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These adipocytokines, through their different mechanisms, result in hypertension (Katagiri, 
Yamada and Oka, 2007). The renin angiotensin aldosterone system also plays a pivotal role in 
the development of cardiovascular events (Li, 2006). The byproduct of this system (angiotensin 
II), induces the release of cytokines and pro-inflammatory transcription factors (nuclear factor 
B) which result in the release of free radicals including reactive oxygen species (Grote, 
Luchtefeld and Schieffer, 2005). Free radicals (ROS) are formed through cellular oxidative 
systems that produce superoxides causing vascular oxidative stress (Grote, Luchtefeld and 
Schieffer, 2005). There are several mechanisms involved which also include vasoconstriction, 
cell growth and vascular inflammation (Li, 2006). Often diabetes and hypertension have 
overlapping disease mechanisms which could explain why some patients with hypertension 
would also have diabetes(Cheung and Li, 2012). Both of these diseases can be characterized 
by chronic inflammation. 
Recent evidence shows that insulin causes sodium retention in the distal tubules of the nephron 
(Miller and Bogdonoff, 2019). This phenomenon is exacerbated in individuals with insulin 
resistance (Reaven and Hoffman, 1987), and as mentioned earlier, an increase in extracellular 
sodium increases blood volume causing an increase in blood pressure, resulting in vascular 
injury.  
2.4.5 Cardiovascular complications  
Cardiovascular adversities arise mainly from the effects (remodeling) exerted on the vascular 
system (Grote, Luchtefeld and Schieffer, 2005). One study estimated a reduction in life 
expectancy of 20% in patients with schizophrenia compared to the general population 
(Newman and Bland, 1991). Adverse effects of antipsychotics increase the risk of 
cardiovascular disease, especially in patients who already present with atherosclerosis or type 
2 diabetes (Buckley and Sanders, 2000; Tschoner et al., 2007). Adverse effects include 
tachycardia, heart arrhythmias, postural hypotension, palpitation and heart failure which was 
the case in almost 75% of patients receiving antipsychotics at therapeutic doses in clinical trials 
or observational studies (Buckley and Sanders, 2000). Apart from suicide and possible 
accidental deaths (Buckley and Sanders, 2000), many patients with schizophrenia demise, 
possibly because the complications associated with metabolic syndrome occur at a molecular 
level. They are not always evident without the appropriate diagnosis, and some people may not 
be aware of the molecular changes occurring in the body leading to death (Vancampfort et al., 
2013; Chiu et al., 2016). Thus, such complications entail different mechanisms. These 
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mechanisms can include direct blockage of muscarinic receptors and 1-adrenoceptors as well 
as sodium, potassium, calcium channels. There is also an indirect blockade mechanism that 
involves blockade of 2-adrenoceptors in the nervous system (Buckley and Sanders, 2000). 
 
2.5 Interventions to combat antipsychotic-induced weight gain 
Weight gain has been associated with treatment non-adherence in patients with schizophrenia 
(Dayabandara et al., 2017). Strategies to counteract weight gain in schizophrenia include 
providing those affected and on antipsychotic therapy with health education (Manu et al., 
2015). Health education includes the promotion of healthy lifestyles behaviours, opting for 
healthier nutritional alternatives and physical activity (Dayabandara et al., 2017). Health 
education is the first step before considering pharmacological interventions. 
It has been proposed that physical activity and a healthy diet should be the main aim of 
counteracting some of the effects of MetS (Li et al., 2017). Lifestyle interventions such as 
exercise have been investigated as potential solutions, especially for diabetes and hypertension 
(Cheung and Li, 2012). The type of physical activities that were deemed suitable for patients 
on antipsychotic therapy was found to be aerobics as well as moderate to high resistance 
training (Curtis et al., 2016), in the same study weight loss was seen after 12 weeks of 
participating in the program. However, of the 28 participants enrolled in the study, only 13% 
of the participants had a significant loss in weight. Although physical activity might work one 
study revealed this intervention was not sustainable in patients with antipsychotic-induced 
weight gain/metabolic syndrome (Bruins et al., 2014).  
The second step is to switch antipsychotics, where possible. Significant weight gain has been 
noted in patients taking clozapine (Bobes et al., 2003), which has proven efficacious in 
treatment-resistant schizophrenia (Kane, 1988a). Ziprasidone, according to a meta-analysis 
study, was the antipsychotic least associated with weight gain (Rummel-Kluge et al., 2010). 
After taking into account side effects, efficacy and the patients preference, physicians are able 
to switch patients to a more weight neutral antipsychotic (Dayabandara et al., 2017). Switching 
antipsychotics to more weight neutral ones has proven effective in some studies (Mukundan et 
al., 1996). Patients who were switched to weight-neutral antipsychotics generally lost weight  
(Mukundan et al., 2007). However, switching from one antipsychotic to another has been 
associated with treatment non-adherence and increased risk of relapse (Stroup et al., 2011), 
hence close monitoring after treatment switch is crucial. 
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Recently, clinicians have adopted a pharmacological approach to treating metabolic adversities 
caused by antipsychotics. A systematic review that looked at the effects of pharmacological 
interventions in the treatment of weight gain discovered that topiramate, sibutramine, 
aripiprazole, reboxetine were effective, while metformin was the most effective agent(Mizuno 
et al., 2014). Most literature supports the use of metformin (Mizuno et al., 2014; Chiu et al., 
2016; de Silva et al., 2016), a biguanide which acts by reducing intestinal glucose uptake as 
well as reducing the hepatic synthesis of glucose (Pharmacology, 2006). Metformin has been 
confirmed to be highly effective in treating antipsychotic-induced weight gain (de Silva et al., 
2016). Although metformin has proven to be the superior pharmacological intervention in 
treating antipsychotic-induced weight gain (Zheng et al., 2015), statins have been found to be 
useful in lowering LDL cholesterol(Stroup et al., 2011).  The use of metformin presents some 
disadvantages such as lactic acidosis especially in elderly patients (Silvestre et al., 2007). These 
adversities are yet to be researched further in patients taking antipsychotics. 
 
2.5.1 Treatment discontinuation  
It has been proven that the use of antipsychotics improves the lives of people with psychotic 
episodes despite the adversities mentioned earlier (Ventriglio et al., 2015). Of the available 
studies that looked at treatment discontinuation as a method of correcting metabolic syndrome, 
a Chinese study which recruited 131 patients discovered that there was no significant change 
in fasting glucose as well as lipid parameters following antipsychotic treatment discontinuation 
(Wu et al., 2014). With treatment discontinuation comes the added risk of relapse (Chiliza et 
al., 2015). With antipsychotic discontinuation, relapse often follows regardless of how long the 
person has been on treatment (Emsley et al., 2013). Relapse does not only complicate the 
course of treatment for the patient, but it often results in hospitalization which has financial 
implications (Ascher-Svanum et al., 2010). Not many studies have investigated the 
consequences of relapse; however, some authors believe relapse results in psychotic 
exacerbations, functional deterioration as well as treatment resistance (Donoghue et al., 2016; 
Emsley, Kilian and Phahladira, 2016). Therefore, patients who show improvement while on 
treatment should not be discontinued from therapy as maintenance treatment often prevents 
relapse, especially if side effects are minimal (Barnes, 2011).  
Treatment non-adherence was found to be the major contributor to relapse in patients 
experiencing first-episode psychosis (Alvarez-Jimenez et al., 2012). On the other hand, some 
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patients relapse while on treatment (Alphs et al., 2012), although some might argue that there 
is no guaranteed method of measuring treatment adherence. Chen et al. (2010) noted that 
relapse rates were higher (79%) in patients who discontinued treatment compared to those on 
maintenance therapy. There are varying definitions of relapse in literature. Some researchers 
use hospital admissions as an indicator of relapse and a flaw in this method is that admission 
rates can be determined by the availability of hospital beds or the ability to provide treatment 
(Donoghue et al., 2016). The same study also noted that a lower relapse threshold resulted in 
higher rates of relapse.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Study site 
The participants of the current study were recruited from the inpatient and outpatient 
departments of Stikland and Tygerberg Hospitals, as well as the clinics and day hospitals within 
the catchment area.  
 
3.2 Study population and data collection 
The current research was part of a broader study which was a randomized, double-blinded, 
placebo-controlled investigation that involved subjects who had been successfully treated for 
2 to 3 years after a first episode of schizophrenia, schizoaffective or schizophreniform disorder 
and who voluntarily opted to discontinue antipsychotic treatment under supervision. Thus, the 
procedures for data collection and the study population had previously been reported (Emsley 
et al., 2014). Briefly, for inclusion in the study, participants could be either male or female 
aged between 16 and 50 years old and had been exposed to at least two years of uninterrupted 
antipsychotic therapy. Participants had a DSM-IV diagnosis of schizophrenia, 
schizophreniform disorder or schizoaffective disorder. Participants were followed from start or 
baseline (remission) until the point of relapse. Follow-up assessments were done every month 
to determine symptom severity, but laboratory samples and measurements were done every six 
months. 
All participants signed informed consent before inclusion in the study. The study was approved 
by the Institution Review Board (Ethics Committee) of Stellenbosch University.  
 
The following data was obtained from the participants at baseline and endpoint (point of 
relapse) 
1) Sociodemographic data 
• Sex 
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• Age of participant 
• Level of education 
• Employment status 
• Type of accommodation 
• Number of children 
• Psychiatric diagnosis 
 
  Laboratory measurements 
• BMI 
• Weight 
• Waist circumference 
• Blood glucose 
• Cholesterol  
 
Treatment  
Participants were all given the injectable long-acting antipsychotic flupenthixol decanoate in 
their respective doses as determined by the participants’ psychiatrist during routine clinical 
care assessment reviews. Each month the flupenthixol decanoate dose was reduced by a factor 
of 0,75 (however, the dose was rounded off to the nearest 10mg for ease of administration). 
Compliance was guaranteed since participants had to visit the healthcare facility to get the 
injection. 
 
3.3 Data analysis  
All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences, 
version 20.0; IBM Corporation, Armonk, New York, USA). Descriptive statistics were 
performed to obtain frequencies of the various parameters. A paired sample Student t-test was 
used to check for any differences between the initial and the endpoint values of all measured 
parameters. Percentages, means and standard deviation of numeric data was determined as well 
as the percentages of categorical data. Chi-square tests were used to compare the categorical 
variables. In order to assess the factors affecting BMI (body mass index), regression (such as 
logistic, linear) were performed to examine the factors. Variables that were significant in 
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bivariate analysis were included in further analyses. Results were considered statistically 
significant at a 95% confidence limit. A statistical test was considered significant if p<0.05. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Results 
 
4.1.1 Sample characteristics 
The total sample in the current study included 33 patients in the age range of 21 years and 
above. The proportion of patients who had secondary school education was 60.6%, 78.8% were 
single, and the majority of the patients were colored (75.8%). Also, 66.7% of the patients spoke 
English, with 78.8% being unemployed. Most of the patients (48.5%) had no children with 
24.5% having at least one child, and 84.8% of the patients lived in their own family house 
(Table 2). 
 
Table2: Socio-demographic characteristics of the study population 
Characteristic Frequency (n) Percentage 
Age group                                                                                                                     
21-25 years                                                                                                                                               13  39.4 
26-30 years                                                                                                                   9    27.3 
31 year and above                                                                                                    11 33.3
Gender    
Male                                                                                                                             24 72.7
Female                                                                                                                         9  27.3 
Ethnic group   
Black African                                                                                                                          5  15.2
Colored                                                                                                                      25 75.8 
White                                                                                                                        3  9.1 
Level of education   
Elementary school                                                                                                 4 12.1 
Secondary school                                                                                                     20 60.6
Matric                                                                                                                          8 24.2 
Technical                                                                                                                    1 3 
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Home language   
Afrikaans                                                                                                                  6  18.2 
English                                                                                                                     22 66.7
isiXhosa                                                                                                                     4 12.1
Other 1  3 
Marital status   
Single                                                                                                                         26 78.8
Married                                                                                                                     3 9.1 
Divorced                                                                                                                    3 9.1 
Cohabiting                                                                                                                 1 3 
Number of children   
0                                                                                                                        16 48.5
1                                                                                                                                   8 24.5
2                                                                                                                                    5 15.2
3                                                                                                                                   2 6.1
4                                                                                                                                 1 3
5                                                                                                                                    1 3
Employment status   
Unemployed                                                                                                             26 78.8 
Casual employment                                                                                               
Full time                                                                                                                                                                  
1 3 
Current accommodation 6 18.2 
Rented room                                                                                                                                                     3 9.1 
Rented house                                                                                                                                                2 6.1 
Own family house                                                                                                   28 84.8
 
4.1.2 Number of weeks it took participants to relapse 
The mean number of weeks to relapse was 39.2 weeks following the gradual discontinuation 
of the antipsychotic treatment (Table 3). The maximum number of weeks before relapse was 
96 weeks while the minimum number of weeks before relapse was 1. By week 32, almost half 
of the study participants had relapsed. 
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Table 3 Number of weeks it took participants to relapse 
 
 
4.1.2 Changes in measured parameters 
An overall comparison of the initial and the endpoint values of the eight parameters measured 
in the current study are represented in Figure 3. 
 
Number of weeks to relapse Number of participants who relapsed 
4 1 
12 4 
16 2 
20 3 
24 3 
28 2 
32 1 
36 1 
40 4 
44 3 
48 1 
52 1 
64 2 
76 1 
88 3 
96 1 
Mean time to relapse 39.2 weeks Total number of participants 33 
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Figure 3: Mean change in measured parameters over time following a change in drug regime. 
The error bars represent the standard deviations from the mean 
 
Following the dose reduction, there was an overall decrease in the patients’ mean waist size, 
weight, fasting blood glucose (FBG) and triglyceride values (Table 4). On the other hand, 
increases were observed with systolic blood pressure (SBP), diastolic blood pressure (DBP) 
and HDL. Only the mean LDL values remain unchanged following treatment. 
Despite these changes, the paired sample t-test analysis revealed that only the changes in FBG 
(p = 0.450), weight (p = 0.018) and waist size (p = 0.006) were statistically significant (p < 
0.05) (Table 5). No statistically significant differences (p > 0.05) were observed between the 
mean HDL, LDL, SBP, DBP and Triglycerides values.
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Table 4: Overall change in metabolic syndrome parameters between initial and endpoint, following dose reduction 
Parameter 
Initial Endpoint 
N Minimum Maximum Mean Std. Deviation N Minimum Maximum Mean Std. Deviation 
Weight 33 49 99 71.67 13.817 33 50 97 69.09 13.333 
Fasting Glucose 33 4 15 5.55 2.346 33 3 10 5.00 1.275 
Systolic Blood 
Pressure 
33 110 151 126.42 11.530 33 95 156 126.67 14.192 
Diastolic Blood 
Pressure 
33 59 98 81.73 9.398 33 66 118 84.15 11.662 
Triglycerides 33 0 7 1.42 1.370 33 0 3 1.21 0.740 
Waist 33 68 118 87.39 14.213 33 66 110 84.15 12.711 
HDL 33 1 2 1.03 0.174 33 1 2 1.06 0.242 
LDL 33 1 4 2.70 0.984 33 1 6 2.70 1.159 
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Table 5: Comparison between initial and endpoint parameters following dose reduction 
Parameters Paired Differences T df P-value 
Mean SD* SE** 95% Confidence Interval of the 
Difference 
Lower Upper 
1 Initial FBG - Endpoint FBG 0.545 1.502 0.261 0.013 1.078 2.086 32 0.045 
2 Initial HDL - Endpoint HDL -0.030 0.305 0.053 -0.138 0.078 -0.571 32 0.572 
3 Initial LDL – Endpoint LDL 0.000 0.935 0.163 -0.332 0.332 0.000 32 1.000 
4 Initial SBP – Endpoint SBP -0.242 12.627 2.198 -4.720 4.235 -0.110 32 0.913 
5 Initial DBP – Endpoint DBP -2.424 12.065 2.100 -6.702 1.854 -1.154 32 0.257 
6 
Initial Triglycerides – Endpoint 
Triglycerides 
0.212 1.244 0.217 -0.229 0.653 0.980 32 0.335 
7 
Initial Weight – Endpoint 
Weight 
2.576 5.911 1.029 0.480 4.672 2.503 32 0.018 
8 
Initial Waist size – Endpoint 
waist size 
3.242 6.260 1.090 1.023 5.462 2.975 32 0.006 
*SD: Standard deviation; **SE: Standard error of the mean. Highlighted values indicate statistical significance
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4.1.2.1 BMI of participants at first visit versus predictor variables 
Table 6 displays the cross-tabulation of BMI at first visit versus predictor variables. BMI was 
categorized as 18.5-24.9 (normal weight), >=25 (overweight). 64% of participants aged 31 years 
and above were >= 25 (overweight), 89% of females were overweight. The observed prevalence 
of normal weight was higher among patients who were never married, while the overweight was 
more predominant amongst the married patients. Considering the racial groups, the study found 
that white patients were more overweight compared to their colored counterparts. In the case of 
employment status, the findings of this study highlight that patients who had fulltime jobs were 
more overweight while the highest proportion of normal weight was found amongst the patients 
with casual employment. 
 
Table 6: Cross-tabulation of BMI at first visit versus predictor variables 
BMI 18.5 – 24.9 >=25   
BMI (first visit) 
Characteristic 
N % N % p-value Chi-
square 
Age group                                                                                                                      
21-25 years                                                                                                                                               6 46 7 54
0.881 0.254 26-30 years                                                                                                                  4 44 5 56
31 year and above                                                                                                    4 36 7 64 
Gender        
Male                                                                                                                             13 54 11 46 0.26 4.968 
Female                                                                                                                         1 11 8 89
Ethnic group       
Black African                                                                                                                          2 40 3 60
0.933 
 
0.139 Colored                                                                                                                      11 44 14 56
White                                                                                                                        1 33 2 67
Level of education       
Elementary school                                                                                                 3 75 1 25  
0.247 
 
4.137 Secondary school                                                                                                    8 40 12 60
Matric                                                                                                                          2 25 6 75
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Technical                                                                                                                    1 100 0 0
Marital status       
Single                                                                                                                         14 54 12 46 
0.88 
 
6.547 Married                                                                                                                     0 0 3 100
Divorced                                                                                                                    0 0 3 100
Cohabiting                                                                                                                 0 0 1 100
Employment status       
Unemployed                                                                                                             11 42 15 58
0.458 
 
1.560 Casual employment                                                                                                                                                                                                                                                            1 100 0 0
Full time 2 33 4 67 
 
 
4.1.2.2 BMI of participants at endpoint versus predictor variables 
Table 7 shows predictor variables at the endpoint. There was an overall decrease in BMI with some 
participants being recorded as being underweight. 
 
Table 7: Socio-demographic factors associated with BMI among participants in South Africa 
BMI Underweight Normal Overweight 
BMI (first visit) 
Characteristic 
N % N % n % P-value Chi-square 
Age group         
21-25 years 2 15 7 54 4 31 0.228 5.634 
26-30 years 0 0 7 78 2 22 
31 year and above 0 0 5 45 6 55 
Gender          
Male 2 8 16 67 6 25 0.077 5.138 
Female 0 0 3 33 6 67 
Ethnic group         
Black African 0 0 3 60 2 40 0.340 4.524 
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Colored 1 4 15 60 9 36 
White 1 33 1 33 1 34 
Level of education         
Elementary school 1 25 3 75 0 0 0.430 5.938 
Secondary school 1 5 10 50 9 45 
Matric 0 0 5 63 3 38 
Technical 0 0 1 100 0 0 
Marital status         
Single 2 8 17 65 7 27 0.510 5.268 
Married 0 0 1 33 2 67 
Divorced 0 0 1 33 2 67 
Cohabiting 0 0 0 0 1 100 
Employment status         
Unemployed 2 8 15 58       9 34 0.808 1.603 
Casual employment 0 0 1 100  0 0 
Full time 0 0 3 50 3 50  
 
 
4.1.2.3 Diabetes mellitus status according to the general characteristics of patients  
Table 8 displays the total observed prevalence of diabetes mellitus status, as well as the prevalence 
of each according to the general characteristics of the participants in the sample. The prevalence 
of normal fasting blood glucose is 66.7%, pre-diabetes was 27.3%, and the diagnosis of diabetes 
mellitus was 6%. Among the different age groups, normal fasting blood glucose was the highest 
among the 21-25 year-old (45.5%), and similarly for diagnosis of diabetes which was 100% in the 
age groups 31 years and above. The observed normal fasting blood glucose was observed amongst 
patients who had matric and technical education while those with elementary education had 75%. 
Normal fasting blood glucose was significantly higher amongst white participants. However, 
Black African patients had the lowest pre-diabetes and diagnosis of diabetes. According to the 
univariate chi-square p-values of table 2, all the independent variables were significantly 
associated with various diabetes except race at a 1% level of significance (p-value <0.001). 
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Table 8: Diabetes mellitus status according to the general characteristics of patients aged 21-50 
years 
 Normal  Pre-diabetes Diabetic   
 N % N % n %  p-value 
Age group                                                                                                                    
21-25 years                                                                                                                                               10 45.5 3 33.3 0 0  0.007 
26-30 years                                                                                                                   8 36.4 1 11.1 0 0
31 year and 
above                                                                                                    
     4     18.1      5     55.6      2      100 
Gender         
Male                                                                                                                             16 72.7 7 77.8 1 50.0 0.045 
Female                                                                                                                         6 27.3 2 22.2 1 50.0
Ethnic 
group 
       
Black 
African                                                                                                                          
  3    60.0    1   20.0     1   20.0  0.710 
Colored                                                                                                                      17 68.0 7 28.0 1 4.0
White                                                                                                                        2 100 1 33.3 0 0
Marital 
status 
       
Single                                                                                                                         19 73.1 7 26.9 0 0 0.033 
Married                                                                                                                     1 33.3 1 33.3 1 33.3
Divorced                                                                                                                    1 33.3 1 33.3 1 33.3
Cohabiting                                                                                                                 1 100 0 0 0 0
Education        
Elementary                                                                                                              3   75.0    1  25.0    0   0  0.021 
Secondary   
Matric                                                                                                                                                                                                                                                              
10 
8
  50.0 
100
   8 
   0 
 40.0 
0
   2 
   0 
 10.0 
   0 
Technical  1   100    0  0    0    0 
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Predictors of BMI at baseline 
The results depicted in Table 9a show the estimates and odds ratios (OR) of socio-demographic 
factors in the outcome of interest (BMI). Out of all the covariates included in the current study, 
gender and marital status were the only significant covariates. Female participants were 1.57 times 
more likely to have a higher BMI at baseline (initial visit) compared to their male counterparts 
(OR=1.57, p = 0.03). Furthermore, married and divorced participants had a higher BMI compared 
to those who were single (OR=2.21, p = 0.02) and (OR=2.08, p = 0.05), respectively. 
 
Table 9a: Estimates and odds ratios of socio-economic and demographic factors on first visit 
BMI 
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Predictors of BMI at endpoint 
There were no statistically significant demographic predictors of baseline BMI (see table 9b). At 
the endpoint visit (point of relapse), married participants were 1.51 times more likely to have a 
higher BMI compared to participants who were not married. Additionally, female participants 
were more likely to have a higher BMI compared to male participants (OR=1.40).  
 
Table 9b: Estimates and odds ratios of socio-economic and demographic factors on endpoint 
BMI  
Variable  Estimate  OR Standard 
error 
p-value  
Dependent variable: First Visit     
Age group in years (ref: 21-25)     
26-30 -1.17 0.31 0.21 0.44 
31+ -0.29 0.75 0.24 0.24 
Gender (ref: male)     
Female  0.45 1.57 0.20 0.03 
Ethnic group (ref: Black African)     
White  0.21 1.23 0.36 0.57 
Colored 0.13 1.14 0.26 0.62 
Educational status (ref: elementary)     
Secondary  0.26 1.30 0.27 0.35 
Matric  0.52 1.68 0.31 0.11 
Technical  0.11 1.12 0.54 0.85 
Marital status (ref: single)     
Married  0.79 2.20 0.31 0.02 
Divorced  0.73 2.08 0.35 0.05 
Cohabiting  0.02 7.40 0.53 0.97 
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Variable  Estimate  OR Standard 
error 
p-value  
Dependent variable: Endpoint      
Age group in years (ref: 21-25)     
26-30 -0.12 0.89 0.27 0.69 
31+ 0.21 1.23 0.29 0.49 
Gender (ref: male)     
Female  0.34 1.40 0.25 0.18 
Ethnic group (ref: Black African)     
White  -0.28 0.76 0.25 0.54 
Colored -0.14 0.87 0.32 0.68 
Educational status (ref: elementary)     
Secondary  0.56 1.75 0.34 0.11 
Matric  0.41 1.51 0.38 0.29 
Technical  0.17 1.19 0.67 0.81 
Marital status (ref: single)     
Married  0.41 1.51 0.39 0.31 
Divorced  0.37 1.45 0.43 0.40 
Cohabiting  0.73 2.08 0.25 0.28 
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4.2 Discussion 
There have been speculations on the potential effects of drug withdrawal on predictors of metabolic 
syndrome in patients experiencing psychosis. Thus, the current study aimed at establishing if there 
was a change in metabolic syndrome parameters following antipsychotic dose reduction in patients 
attending a hospital in the Western Cape, South Africa. The results of the study revealed that 
weight, fasting blood glucose, and BMI all decreased significantly from baseline to endpoint. On 
the other hand, lipids, diastolic and systolic blood pressure did not improve from baseline to 
endpoint. An overall decrease in BMI was observed in the majority of patients, following the 
reduction in the treatment dose. Females were more likely to have a higher BMI at baseline 
compared to males. Married and divorced participants were also more likely to have a higher BMI 
at baseline compared to those who were single. 
 
 Our study findings seem to differ from Wu et al., as their study reported an insignificant decrease 
in glucose; however, they also found an insignificant change in lipid parameters. Their study 
compared patients who were drug naïve and had schizophrenia, those who had first-episode 
psychosis and patients who had schizophrenia and were on treatment. They further concluded that 
antipsychotic discontinuation had no positive effect on glucose and lipid parameters (Wu et al., 
2014). Several factors could account for the difference between the findings of the current study 
and those of Wu and colleagues. Firstly, the sample sizes differed in that Wu et al. worked with 
131 participants compared to 33 included in our study. This could have affected the strength of the 
statistics and, thus, the observed outcome in both studies. Secondly, the subjects in Wu et al. were 
not placed on the same antipsychotic, while our study only focused on participants who were put 
on flupenthixol treatment. Our study shows that antipsychotic discontinuation does improve 
fasting blood glucose, weight and BMI. The decrease in BMI is consistent with the findings of a 
recently published discontinuation study on adolescents, which revealed a significant decrease in 
BMI after treatment discontinuation (Upadhyay et al., 2019). However, with that being said, the 
loss of weight following antipsychotic discontinuation needs to be balanced by the risks associated 
with relapse. Hence, recruitment of study participants for our study was stopped due to the high 
rates of relapse following treatment discontinuation with one patient attempting suicide (Emsley 
et al., 2014). 
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4.2.1 Participant’s demographic information 
Socio-demographic factors have been found to be associated with weight gain in upper-income 
countries; however, this has been more evident in low and middle countries where there is a 
stronger association between weight and socio-demographic factors (Ball and Crawford, 2005). 
The major risk factors associated with MetS were being a white female and older than 35 years 
and of white descent. These findings are similar to those of another study done in South Africa 
(Saloojee, Burns and Motala, 2016); however, due to the lack of Indian participants in the current 
study population, it not possible to determine the racial impact based on South Africa’s diversity.  
 
The majority of our participants were unemployed, which in keeping with other studies. One study 
done in the UK, Germany and France, recorded less than 12% of their participants who had 
schizophrenia were employed and capable of taking care of themselves financially without 
assistance from social welfare (Marwaha et al., 2007). One would assume that this figure would 
be lower in low- and middle-income countries due to poverty and scarcity of employment even for 
those who are qualified and do not have a mental illness. However, the study mentioned above had 
most of the 12% in elementary occupations requiring the use of hand-held tools and physical effort,  
e.g. farm workers and only 1% in senior positions. The present study had 78.8% of the participants 
unemployed, apart from reasons related to mental health, South Africa currently has one of the 
highest rates of unemployment even for qualified graduates who can function well cognitively 
(Banerjee et al., 2008). Not to tell people that suffer from schizophrenia do not make it through to 
technical education, as we have discovered a fair number (Marwaha et al., 2007). However, they 
might experience challenges, especially those who have early-onset schizophrenia (Okasha, Kamel 
and Sadek, 1979). One participant in the current study had achieved a technical education level.  
 
4.2.2 Overall change in patients’ parameters 
The major phenotypical signs of metabolic syndrome in schizophrenia patients taking 
antipsychotics are the increase in weight, BMI and waist circumference (Kane, 1988a; Reynolds 
and Kirk, 2010; Correll, Lencz and Malhotra, 2011; Wu et al., 2014; Chiliza et al., 2015). In the 
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current study, a significant change was observed for weight (p=0.018) and waist circumference (p 
= 0.006) following the discontinuation of antipsychotic therapy. The participants in our study had 
gained weight and experienced an increase in waist circumference; however, by reducing the dose 
of flupenthixol, it was discovered that there was an overall decrease in these parameters. This was 
more evident for those participants who took longer to relapse. Some researchers, however, believe 
that weight gain is not necessarily related to the dose of antipsychotics, therefore making dose 
reduction an unreliable strategy in dealing with weight gain (Chiliza et al., 2015). Weight gain is 
probably one of the few modifiable risk factors in schizophrenia which require closer monitoring; 
however, there has been inadequate attention to this until recently (Allison et al., 2009). Upadhyay 
et al. (2019) also noticed a reduction in BMI in their study population. It was also evident that 
although the participants’ BMI decreased, the new BMI was not the same as their initial BMI prior 
to taking antipsychotics treatment which means that adolescents on antipsychotic treatment who 
had gained a considerable amount of weight could remain obese. 
 Lipid parameters such as HDL, LDL, and triglycerides revealed no statistically significant change. 
These findings are consistent with those obtained by Wu et al. (2014), revealing that there is no 
significant change in lipid profile in schizophrenia patients after treatment discontinuation. An 
alarming discovery was the increase in total cholesterol and triglycerides in a cohort of Taiwanese 
patients after only three weeks of antipsychotic therapy (Huang and Chen, 2005). Alterations in 
lipid profiles often result in coronary heart disease as well as type two diabetes. Such adversities 
have led to an estimated 20% reduction in the life expectancy of patients with schizophrenia 
compared to the general population (Newman and Bland, 1991; Huang and Chen, 2005; Ventriglio 
et al., 2015).  
No improvement was observed in blood pressure readings as well. There seems to be a lack of 
research in the alterations in blood pressure attributed to the use of antipsychotics. However, one 
study suggested that an increase in weight could be the driving force for hypertension. The 
mechanism by which blood pressure is elevated in patients with metabolic syndrome could be 
secondary to obesity and alterations in lipid profile (Re, 2009). Patients with increased weight 
usually require more pressure to move blood around the body, when fat is situated around the 
abdominal area, this thickens arteries, making them stiff further increasing pressure required to 
transport blood (Dr Robin Miller, 2011). 
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However, our study found an improvement in fasting glucose (p = 0.045) (SD = 1.502). Some 
researchers claim that glucose abnormalities might be intrinsic to schizophrenia even before any 
initiation of antipsychotic therapy (Guest et al., 2010; Freyberg et al., 2017). Wu et al. (2014) 
concluded that the disturbances that occur with glucose and lipid metabolism are associated with 
both schizophrenia and antipsychotics. The results of the current study support the potential 
contribution of antipsychotics to the increased rates of diabetes mellitus in people with 
schizophrenia, as diabetes mellitus is highly prevalent amongst people with schizophrenia 
compared to the general population (Schoepf et al., 2012). Older participants were more likely to 
have diabetes compared to their younger counterparts (Selvin and Parrinello, 2013). This could be 
attributed to illness duration whereby older participants might have had schizophrenia for longer 
than the younger participants and hence increasing the chances of presenting with diabetes (De 
Hert et al., 2006). 
 
4.2.3 BMI of participants versus predictor variables 
The burden of being overweight affected 64% of the participants and mostly those participants 
who were aged 31 and above. Participants who were 31 years and above had a higher BMI at 
baseline as well as an endpoint, although there was a general drop at endpoint this group still had 
most of its participants overweight. A positive correlation between age and weight has been 
observed in some studies (Kelly et al., 2008; Hales et al., 2015). An increase in BMI with age 
could be attributed to a more prolonged illness duration or increased exposure to predisposing 
factors. The CATIE study also had similar results where older participants were more likely to 
have metabolic syndrome, most of whom were  white and female (Meyer et al., 2005). 
 
The results of our study revealed that females were more prone to weight gain compared to their 
male counterparts. This is in line with the findings of other studies which suggest that the female 
gender was more prone to weight gain (Burke et al., 1996; Wang et al., 2010; Chadda et al., 2013). 
However, in lower- and middle-income countries (LMIC), this could differ depending on the 
economic status of the majority of people. In LMIC, weight gain is associated with a better 
economic standing whereas in the upper-income countries it is vice versa (Dinsa et al., 2012). 
Although the present study did not adequately represent South Africa’s diverse racial makeup, 
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(Saloojee, Burns and Motala, 2016) found that metabolic syndrome could also be race-dependent 
in which some racial groups are more prone to metabolic abnormalities compared to others. Their 
study confirmed that participants of Indian were more prone to MetS compared to Black Africans, 
which could be as a result of Indian participants having a high visceral fat deposition even at low 
BMI and being more prone to diabetes mellitus (Palaniappan et al., 2011). It should, however, be 
noted that given the small number of participants examined in the current study, the results 
presented should be interpreted with caution. Also, we found that white females were obese 
compared to females of other racial groups although, Black African females were not too far 
behind. This is contrary to the findings made by Burke (Burke et al., 1996), where it was found 
that people Black Africans were generally more overweight compared to white people. This could 
be attributed to the relatively small sample size of the current study. The same study by Burke 
observed weight gain changes in young participants for five years, and although many participants 
who were Black Africans  presented obese at baseline, they still gained a considerable amount of 
weight during the study period. In some African cultures, women who carry more weight are 
considered healthier especially in regions where poverty is rife (Costello-Nichitas, 1987). Also, 
African women do not necessarily experience the same societal pressures experienced by white 
women when it comes to weight and therefore do not see the need for regular weight loss exercises 
compared to their white counterparts (Burke et al., 1996). This might change due to globalization 
and adoption of the western culture by African females. Malnutrition and obesity are both 
considered public health problems (Harrison, 2006; Akadri et al., 2016) and depending on the 
region one is at, one of the two usually dominates. Weight gain can cause obesity-related diseases 
in schizophrenia patients such as type 2 diabetes and cardiovascular disease (Ferrannini et al., 
1997; Mackin, Watkinson and Young, 2005; Reynolds and Kirk, 2010; Chang and Lu, 2012). 
 
It was found that single (unmarried) participants were less prone to weight gain. There is evidence 
in the literature supporting the notion that changes in marital status affect changes in weight (Sobal, 
1992). Other studies have stated explicitly that women who get married gain more weight 
compared to married males (Janghorbani et al., 2008), which is contradictory to findings of other 
studies such as (Sobal, 1992) who found that males gained more weight than females. The reason 
for this could be that women who are single experience pressure in attracting a potential life partner 
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as well as being economically viable through appearance (McKinley and Hyde, 1996), although it 
could be the other way around depending on geographical region or culture.  
 
4.2.4 Diabetes status according to the general characteristics of patients  
Some researchers believe that the increased prevalence of Type 2 diabetes in schizophrenia 
patients might be as a result of Type 2 diabetes sharing a common intrinsic inflammatory disease 
pathway with schizophrenia (Perry et al., 2016). Lorenzo et al. (2003)  suggested that metabolic 
syndrome is a predictor of diabetes. Some studies discovered that the mean age of acquiring full 
diabetic status was 41 years of age (Cohen, 2007). A global study discovered that in developed 
countries, most people with diabetes were over 60 years of age, while in developing countries it 
was most common among the working class with age varying between 40 and 60 years (Whiting 
et al., 2011). Although the age threshold of the patients in the current study was below 60, it was 
also observed that participants over the age of 31 were most likely to have diabetes compared to 
the younger participants. This could be a result of illness duration or even prolonged exposure to 
antipsychotic therapy which could have increased the patient's chances of having diabetes 
(Mitchell et al., 2013). This is further supported by the observation that most people are diagnosed 
with schizophrenia in their mid-20s (Kam, Singh and Upthegrove, 2015). Insulin sensitivity 
decreases in both obese males and females as they get older (Gale and Gillespie, 2001). It was also 
discovered that patients who had schizophrenia but did not have diabetes were, in most cases, on 
antipsychotics that had low metabolic risks, e.g. ziprasidone (Nielsen, Skadhede and Correll, 
2010a). 
 
In Africa, the prevalence of diabetes is estimated to be 4.7% by 2030 and 7.7% globally in the 
same year (Whiting et al., 2011). Previous literature associated increased risk of diabetes with 
being female; however, it has been proven that those studies were, in fact, biased (Gale and 
Gillespie, 2001). The present study discovered that diabetes was equally present in both gender 
groups. Normal fasting blood glucose was highest among participants between the ages of 21 and 
25 years. Younger participants might have had a shorter illness duration to have been exposed to 
the predisposing factors of diabetes, including the duration on high metabolic syndrome risk 
antipsychotics which could lead to weight gain and later diabetes (Nielsen, Skadhede and Correll, 
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2010a). Older participants were at higher risk of diabetes, and this could be a result of other 
comorbidities such as hypertension and high cholesterol levels (Lorenzo et al., 2003). Slamming 
high metabolic risk antipsychotics do not necessarily work in the best interest of the patient as 
some of these antipsychotics (clozapine) have been proven to be efficacious in the treatment of 
resistant schizophrenia, and therefore psychiatrists have to risk metabolic syndrome for a better 
quality of life (Kane, 1988b). 
Overall diabetes did not seem to be a major health issue in the study population of the current 
study. The participant’s race did not seem to play a role in the diabetes status of the participants 
(p>0.05). Saloojee et al. (2016) discovered that full metabolic status was more prevalent in Indian 
participants compared to other racial groups, which cannot be reported in the current study as it 
did not represent South Africa’s racial diversity adequately. Obesity could have been one of the 
predisposing factors leading to diabetes in these participants (Saklayen, 2018). Black African 
participants had the lowest diagnosis of diabetes. This could be a result of socio-economic factors 
such as poverty, and in many instances, there is no luxury of choosing what to eat, meals are based 
on what is available.  
  
 
 
43 
 
CHAPTER 5 
CONCLUSION, LIMITATIONS AND RECOMMENDATIONS 
5.1 Conclusion 
 
The importance of monitoring patients taking antipsychotics is crucial and should be considered 
as part of routine patient clinical care. Patients taking antipsychotics are at risk of weight gain as 
well as the other disease burdens that come with obesity. In the current study, it was shown that 
dose reduction does overall decrease the BMI of participants taking a long-acting injectable 
antipsychotics. The lipid profiles of the participants were moderately affected by dose reduction 
and the change in blood pressure from the beginning of the study was insignificant. The issue of 
non-compliance and variations in weight gain attributed to the use of different antipsychotics was 
resolved by the use of the injectable antipsychotic. The study was able to keep almost all of its 
participants, although there were the inevitable cases of relapse. Although dose reduction might 
have worked in reducing BMI, the challenge that arose was that of relapse, making treatment with 
antipsychotics a difficult task of balancing a risk-benefit ratio scale.  
 
5.2 Limitations 
The present study presented with a number of limitations, the most evident being the relatively 
small sample size (N=33) that lacked a healthy control. Recruitment of more participants had to 
be stopped because participants started relapsing, with some even attempting suicide. Factors such 
as diet, smoking, level of physical activity and drug abuse were not measured. This study is also 
limited in that it only assessed metabolic syndrome in patients using only one antipsychotic 
(flupenthixol), which means results cannot be generalized for all first-episode psychosis patients. 
Another noteworthy factor would be the duration of the study might not have been long enough to 
significantly improve MetS, this factor is further hindered by relapse as patients tend to relapse 
soon before any changes can be observed. As soon as patients relapsed, they went back onto 
treatment to eliminate illness progression. Regardless of the above-mentioned limitations, there is 
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little research available on strategies to reverse metabolic risk factors and the few available studies 
are not particular on which antipsychotic the participants are on. The major strength of this study 
is that all the participants were given an injectable antipsychotic, which meant adherence to 
treatment was guaranteed, as the injectable was administered at a health facility. 
5.3 Recommendations 
Based on the findings of the current study, it is recommended that: 
1. A more robust study be conducted to take into account a larger sample size and for a longer 
period. This should also involve different regions of the country so that a better 
appreciation of race can be achieved. 
2. The lack of a healthy control population could also affect the overall conclusions drawn in 
the current study. As such, further studies would be required to ascertain that parameters 
such as weight gain were actually a result of treatment with antipsychotics. 
3. Different dosages of antipsychotics present with different side effects and at different 
levels. This could affect the outcome of discontinuing treatment, as all the patients were 
not put on the same dosage. It would, therefore, be important to conduct further studies 
involving participants undergoing the same level of treatment. 
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